cbdMD Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY Revenue (est.)
$22.2Mnext fiscal year
FY EPS (est.)
-$0.19next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q4 and Full Year Fiscal 2026 Earnings Release | 17 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Net Sales Growth (YoY) Quarterly19.0%
Gross Profit Margin Quarterly58.0%
Direct-to-Consumer (DTC) Net Sales Share Quarterly67.0%
Wholesale Net Sales Share Quarterly33.0%
Watch Items
- Going Concern Warning and Cash RunwayTrigger: Free cash flow trend below -$2.7 million annually or cash on hand dropping below $1.5 millionAction: Evaluate utilization of the $20 million equity line of credit (ELOC) or additional Series C preferred stock private placements to support working capital.
- NYSE American Continued Listing ComplianceTrigger: Stock price consistently trading below minimum thresholds or net book value dropping below $2.0 millionAction: Monitor exchange notifications and implement capital restructuring or reverse stock splits if necessary to maintain listing.
- Integration of Bluebird BotanicalsTrigger: Failure to realize anticipated operational synergies or sequential revenue contraction in the Bluebird brandAction: Review brand portfolio consolidation, marketing spend efficiency under the newly appointed CMO, and supply chain optimization.
Research as of 20 Jun 2026